| abstract |
Reversible and irreversible inhibitors of brutonyl tyrosine kinase (Btk) are disclosed herein. Also disclosed are pharmaceutical compositions comprising these compounds. Methods for using Btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or diseases, heterologous immune diseases or conditions, cancers including lymphomas, and inflammatory diseases or diseases are described. |